The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …

Background & Aims There is debate over whether patients with inflammatory bowel
diseases (IBD) treated with biologics that are not tumor necrosis factor antagonists (such as …

Background Both vedolizumab and ustekinumab can be considered for the treatment of
Crohn's disease (CD) when anti‐TNF treatment fails. However, head‐to‐head trials are …

Background Women with inflammatory bowel diseases (IBD) often receive biologicals
during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed …

Background There is no head‐to‐head trial comparing ustekinumab and vedolizumab in
patients with Crohn's disease (CD) refractory to anti‐tumour necrosis factor (anti‐TNF). Aim …

Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in
moderate‐to‐severe ulcerative colitis (UC), but few real‐world data are currently available …

Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in
ulcerative colitis (UC), but few real‐life long‐term data are currently available. Aims To …

Background The best option between vedolizumab and ustekinumab after anti‐tumour
necrosis factor (TNF) failure remains unclear in Crohn's disease. Aims To compare the short …

Aims Ustekinumab is a monoclonal antibody that selectively targets p40, a shared subunit of
the cytokines interleukin [IL]-12 and IL-23. It is registered for the treatment of inflammatory …

Background Subcutaneous (SC) vedolizumab is effective in inflammatory bowel diseases
(IBD) when administered after induction with two infusions. Aim To assess the effectiveness …